Specifically, it is alleged that Defendants made materially false and misleading statements about: (1) managed care's acceptance of GOCOVRI (2) the breadth of insurer coverage for GOCOVRI prescriptions and (3) the impact of the Company's commercialization efforts. The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Food and Drug Administration for the treatment of levodopa-induced dyskinesia. Adamas's primary product is GOCOVRI, an extended-release formulation of amantadine (formerly referred to as ADS-5102), which has been approved by the U.S. Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the 'Exchange Act') and Rule 10b-5 promulgated thereunder.ДЄdamas is a commercial stage pharmaceutical company that specializes in developing drug treatment therapies for chronic neurologic disorders. 4:19-cv-08051, is on behalf of a class consisting of investors who purchased or otherwise acquired Adamas securities between Augand September 30, 2019, both dates inclusive (the 'Class Period'). The class action, filed in the United States District Court for the Northern District of California, and docketed under Case No. Merriweather (collectively, 'Adamas', 'the Company' or 'Defendants'). ('FDA') and Thornton Law Firm LLP ('Thornton') announced today that they have filed a securities class action lawsuit on behalf of Plaintiff Ali Zaidi against Adamas Pharmaceuticals, Inc., Gregory T. DENVER, CO / ACCESSWIRE / Decem/ Franklin D.

Azar pc